Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
52.77
USD
+1.70%
+2.31%
+30.88%
Presenter SpeechLilia-Celine Lozada (Analysts)Hi, everyone. Thanks for joining. I'm Lily Lozad...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
RxSight Launches New Light Adjustable Lens Product
Apr. 04
MT
RxSight, Inc. Announces Commercial Launch of its Newest Light Adjustable Lens??, the LAL+??, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
Apr. 04
CI
Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing
Apr. 02
MT
Needham Raises Price Target on RxSight to $64 From $53, Maintains Buy Rating
Feb. 29
MT
Oppenheimer Adjusts RxSight Price Target to $61 From $54, Maintains Outperform Rating
Feb. 29
MT
RxSight's Q4 Adjusted Loss Narrows, Sales Increase; Reiterates 2024 Revenue Guidance
Feb. 29
MT
Transcript : RxSight, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28
Earnings Flash (RXST) RXSIGHT Reports Q4 Revenue $28.6M, vs. Street Est of $27.9M
Feb. 28
MT
Rxsight, Inc. Reiterates Earnings Guidance for the Full Year 2024
Feb. 28
CI
RxSight, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 28
CI
RxSight, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 28
CI
Rxsight Insider Sold Shares Worth $1,350,000, According to a Recent SEC Filing
Feb. 16
MT
Rxsight Insider Bought Shares Worth $406,673, According to a Recent SEC Filing
Feb. 15
MT
RxSight Insider Sold Shares Worth $525,939, According to a Recent SEC Filing
Feb. 13
MT
Stifel Adjusts Price Target on RxSight to $54 From $45, Maintains Buy Rating
Feb. 12
MT
Rxsight Insider Sold Shares Worth $1,182,660, According to a Recent SEC Filing
Feb. 07
MT
Rxsight Insider Sold Shares Worth $500,004, According to a Recent SEC Filing
Feb. 02
MT
Rxsight Insider Sold Shares Worth $351,411, According to a Recent SEC Filing
Feb. 02
MT
Rxsight Insider Sold Shares Worth $1,403,120, According to a Recent SEC Filing
Feb. 02
MT
Rxsight Insider Sold Shares Worth $1,496,706, According to a Recent SEC Filing
Jan. 29
MT
Oppenheimer Raises RxSight Price Target to $54 From $50, Maintains Outperform Rating
Jan. 29
MT
RxSight Insider Sold Shares Worth $480,006, According to a Recent SEC Filing
Jan. 23
MT
Rxsight Insider Sold Shares Worth $292,555, According to a Recent SEC Filing
Jan. 19
MT
Oppenheimer Raises RxSight Price Target to $50 From $46, Maintains Outperform Rating
Jan. 16
MT
Transcript : RxSight, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:00 PM
Jan. 10
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Companyâs RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patientâs vision outcomes.
More about the company
Last Close Price
52.77
USD
Average target price
62.62
USD
Spread / Average Target
+18.68%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1